Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2012 by Stanford University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Michael Ostacher, Stanford University
ClinicalTrials.gov Identifier:
NCT00572117
First received: December 10, 2007
Last updated: December 12, 2012
Last verified: December 2012

December 10, 2007
December 12, 2012
August 2007
March 2014   (final data collection date for primary outcome measure)
Amount of alcohol consumed [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00572117 on ClinicalTrials.gov Archive Site
  • Safety and tolerability of topiramate. [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
  • Effect of decreased drinking on mood symptoms [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder
Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder

The purpose of this study is determine whether the use of topiramate is effective in the treatment of alcohol dependence (i.e. decreases drinking) in patients with bipolar disorder.

Alcohol and substance use disorders are more common in bipolar disorder bipolar disorder than in any other DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) Axis I disorder, estimated to occur in up to 60% of patients with bipolar disorder. Alcohol use is associated with poor outcome in bipolar disorder, and yet these co-occurring conditions are understudied. To date, there is only one published placebo-controlled trial of an agent for the treatment of alcohol dependence alcohol dependence in bipolar disorder. The purpose of the proposed study is to evaluate the efficacy of a topiramate as a treatment for alcohol dependence in patients with bipolar disorder. This is a 12-week, randomized, placebo-controlled study of the efficacy of topiramate adjunctive to standard treatment for bipolar disorder in patients with alcohol dependence and bipolar disorder. Additional aims of the study are to document the safety and tolerability of topiramate in this population, and to evaluate to effect of decreased drinking on mood symptoms. The study involves the enrollment of a total of 80 patients with co-occurring alcohol dependence and bipolar disorder over the course of 40 months at the Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program (BCRP) (www.manicdepressive.org). With a conservative estimate of a 30% dropout rate, approximately 56 of the 80 patients with these two comorbid conditions will complete 12 weeks treatment with either topiramate or placebo.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Bipolar Disorder
  • Alcoholism
  • Alcohol Dependence
Drug: Topiramate
Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
Other Name: Topamax
  • Placebo Comparator: Placebo (inert pill) Arm
    Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. Subjects will receive placebo pills identical to the active pills (pills that contain the study drug, topiramate) for the 12 treatment weeks of the study and will have the pills discontinued over the next four weeks of the study. All subjects will be re-evaluated at 26 and 52 weeks.
    Intervention: Drug: Topiramate
  • Experimental: Topiramate
    Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. The pills will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
    Intervention: Drug: Topiramate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
80
July 2014
March 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 18+
  2. Written informed consent.
  3. Meet DSM-IV criteria (by SCID) for alcohol dependence.
  4. Meet DSM-IV criteria (by SCID) for bipolar disorder I or II disorder.
  5. ≥ 8 heavy drinking days (defined as ≥ 5 standard drinks per day for men, ≥ 4 standard drinks per day for women) in the prior 4 weeks.
  6. During the baseline visit, patients must be on a stable dose of accepted maintenance treatment for bipolar disorder for the past 4 weeks. If the subject is on more than one agent, at least one agent must be adequately dosed.
  7. Antidepressant treatment is permitted if the dose has been stable for the past 4 weeks.

Exclusion Criteria:

  1. Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy). Because of the risk of the lowering of oral contraceptive blood levels with topiramate, women whose sole means of contraception is oral contraceptives or hormonal implants will be asked to use an additional barrier method of birth control during treatment with the study drug.
  2. Women who are lactating.
  3. Age under 18.
  4. Patients who do not have ≥ 8 heavy drinking days in the 4 weeks prior to the baseline visit.
  5. Important alcohol withdrawal symptoms (Clinical Institute Withdrawal Assessment for Alcohol-Revised, CIWA-Ar, score > 15)
  6. Urine toxicological screen positive for amphetamines or cocaine.
  7. Meets DSM-IV criteria for current substance dependence for drugs other than cannabis or nicotine.
  8. Currently meets full DSM-IV criteria for manic, hypomanic, or mixed episode.
  9. Serious suicide or homicide risk, as assessed by evaluating clinician.
  10. Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease or uncontrolled seizure disorder.
  11. History of nephrolithiasis, or treatment with any drug associated with nephrolithiasis.
  12. Current treatment with zonisamide.
  13. Current treatment with any carbonic anhydrase inhibitors, including acetazolamide, dorzolamide, and methazolamide.
  14. Current treatment with any drug known to decrease drinking.
  15. Subjects who have begun a new psychosocial treatment within 12 weeks of study enrollment. Subjects receiving psychosocial treatment that has been stable for at least 12 weeks prior to study entry, however, will be permitted to enroll in the study.
  16. Any psychotic disorder, including schizoaffective disorder (current or past).
  17. Clinical or laboratory evidence of untreated hypothyroidism.
  18. Patients with a diagnosis or history of glaucoma
  19. Patients requiring excluded medications (see table below for details).
  20. Psychotic features in the current episode or a history of a psychotic disorder, as assessed by SCID.
  21. Past intolerance to topiramate.
  22. Any use of topiramate in the past 12 months.
  23. Any investigational psychotropic drug within the last 3 months.
Both
18 Years and older
No
Contact: Michael J. Ostacher, MD, MPH 650-493-5000 ext 60494 ostacher@stanford.edu
Contact: Iola Gwizdowski 617-493-5000 ext 67571 Iola.Gwizdowski@va.gov
United States
 
NCT00572117
TIL-NIAAA-016340-01, K23AA016340
No
Michael Ostacher, Stanford University
Stanford University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigator: Michael J. Ostacher, MD, MPH Stanford University
Stanford University
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP